Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000991873 | SCV001143707 | uncertain significance | not provided | 2018-09-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001302557 | SCV001491771 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2P; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9 | 2021-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces serine with threonine at codon 179 of the DAG1 protein (p.Ser179Thr). The serine residue is weakly conserved and there is a small physicochemical difference between serine and threonine. This variant is present in population databases (rs201869343, ExAC 0.05%). This variant has not been reported in the literature in individuals affected with DAG1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000991873 | SCV003834249 | uncertain significance | not provided | 2020-10-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001302557 | SCV005662597 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2P; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9 | 2023-12-29 | criteria provided, single submitter | clinical testing |